Profound Medical Corp. ("Profound" or the "Company") is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the "Offering").

TUSK Practice Sales ("TUSK") wraps 2025 as a year defined by disciplined execution, healthcare industry resilience, and a continued commitment to healthcare practice owners. In 2025, TUSK represented ...

The dermatology CRO market specializes in providing outsourced research services that span the entire drug development ...

Recordings, the lawsuit states, were transmitted to Abridge, a Pittsburgh-based technology company that has recently received ...

Self-administered HPV tests involve inserting a plastic tube — similar to a tampon — into the vagina, then twisting the ...

Liv Hospital, the pioneer provider of personalized care, relies on the principle that each patient's cancer is different. The team undertakes to target the specific causes of a person's cancer rather ...

Artificial intelligence is making its way into every aspect of life, including cancer prevention. New technology at MUSC is ...

Cardiovascular disease remains a leading global cause of death, and we break down its pathology, risk factors, and the ...

A tool for spotting pancreatic cancer in routine CT scans has had promising results, one example of how China is racing to ...

This guide deconstructs the pathophysiology of UTIs, exploring the anatomical risks in women, and the efficacy of antibiotic ...